Non-small Cell Lung Cancer Survival Estimation Through Multi-omic Two-layer SVM: A Multi-omics and Multi-Sources Integrative Model

被引:5
|
作者
Manganaro, Lorenzo [1 ,6 ]
Sabbatini, Gianmarco [1 ]
Bianco, Selene [1 ]
Bironzo, Paolo [2 ]
Borile, Claudio [3 ]
Colombi, Davide [1 ]
Falco, Paolo [1 ]
Primo, Luca [4 ,5 ]
Vattakunnel, Shaji [1 ]
Bussolino, Federico [4 ,5 ]
Scagliotti, Giorgio Vittorio [2 ]
机构
[1] AizoOn Technol Consulting, Str Lionetto 6, I-10146 Turin, Italy
[2] Univ Torino, S Luigi Hosp, Dept Oncol, Med Oncol Div, Reg Gonzole 10, I-10043 Orbassano, Italy
[3] CENTAI, Corso Inghilterra 3, I-10138 Turin, Italy
[4] Univ Torino, Dept Oncol, Str Provinciale 142,Km 3-95, I-10060 Candiolo, Italy
[5] Candiolo Canc Inst IRCCS FPO, Str Provinciale 142,Km 3-95, I-10060 Candiolo, Italy
[6] AizoOn Technol Consulting, Str Lionetto 6, I-10146 Turin, TO, Italy
关键词
Multi-omics; multi-layer support vector machine; disease-free survival; machine learning; non-small cell lung cancer; predictive medicine; ENRICHMENT ANALYSIS; MUTATIONS; EXPRESSION;
D O I
10.2174/1574893618666230502102712
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background The new paradigm of precision medicine brought an increasing interest in survival prediction based on the integration of multi-omics and multi-sources data. Several models have been developed to address this task, but their performances are widely variable depending on the specific disease and are often poor on noisy datasets, such as in the case of non-small cell lung cancer (NSCLC).Objective The aim of this work is to introduce a novel computational approach, named multi-omic two-layer SVM (mtSVM), and to exploit it to get a survival-based risk stratification of NSCLC patients from an ongoing observational prospective cohort clinical study named PROMOLE.Methods The model implements a model-based integration by means of a two-layer feed-forward network of FastSurvivalSVMs, and it can be used to get individual survival estimates or survival-based risk stratification. Despite being designed for NSCLC, its range of applicability can potentially cover the full spectrum of survival analysis problems where integration of different data sources is needed, independently of the pathology considered.Results The model is here applied to the case of NSCLC, and compared with other state-of-the-art methods, proving excellent performance. Notably, the model, trained on data from The Cancer Genome Atlas (TCGA), has been validated on an independent cohort (from the PROMOLE study), and the results were consistent. Gene-set enrichment analysis of the risk groups, as well as exome analysis, revealed well-defined molecular profiles, such as a prognostic mutational gene signature with potential implications in clinical practice.
引用
收藏
页码:658 / 669
页数:12
相关论文
共 50 条
  • [1] Multi-omics integrative analysis and survival risk model construction of non-small cell lung cancer based on The Cancer Genome Atlas datasets
    Luan, Mingyuan
    Song, Fucheng
    Qu, Shuyuan
    Meng, Xi
    Ji, Junjie
    Duan, Yunbo
    Sun, Changgang
    Si, Hongzong
    Zhai, Honglin
    ONCOLOGY LETTERS, 2020, 20 (04)
  • [2] A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer
    Ye, Qing
    Falatovich, Brianne
    Singh, Salvi
    Ivanov, Alexey V.
    Eubank, Timothy D.
    Guo, Nancy Lan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (01)
  • [3] Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer
    Monkman, James
    Kim, Honesty
    Mayer, Aaron
    Mehdi, Ahmed
    Matigian, Nicholas
    Cumberbatch, Marie
    Bhagat, Milan
    Ladwa, Rahul
    Mueller, Scott N.
    Adams, Mark N.
    O'Byrne, Ken
    Kulasinghe, Arutha
    IMMUNOLOGY, 2023, 169 (04) : 487 - 502
  • [4] Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients
    Mei, Ting
    Wang, Ting
    Zhou, Qinghua
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [5] Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer
    Wu, Rui
    Wei, Kunchen
    Huang, Xingshuai
    Zhou, Yinge
    Feng, Xiao
    Dong, Xin
    Tang, Hao
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [6] Role of the “inflammation-immunity-metabolism” network in non-small cell lung cancer: a multi-omics analysis
    Jingqi Zhang
    Liping Lin
    Wenyuan Li
    Jing Guo
    Discover Oncology, 16 (1)
  • [7] Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer
    Alhushki, S. K.
    Al-Muhtaseb, A.
    Abushukair, H.
    Abulrous, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S442 - S443
  • [8] Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer
    Zheng, Yang
    Tang, Lili
    Liu, Ziling
    BMC CANCER, 2021, 21 (01)
  • [9] Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review
    Bourbonne, Vincent
    Geier, Margaux
    Schick, Ulrike
    Lucia, Francois
    BIOMEDICINES, 2022, 10 (06)
  • [10] Integrative Multi-Omics Analysis of Identified NUF2 as a Candidate Oncogene Correlates With Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer
    Chen, Mengqing
    Li, Shangkun
    Liang, Yuling
    Zhang, Yue
    Luo, Dan
    Wang, Wenjun
    FRONTIERS IN ONCOLOGY, 2021, 11